Ira ira Haavisto

Dr. Ira ira Haavisto


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 October 2022 in JMIR Research Protocols
Verified
Journal Article
Open access
GPGreta Pettini
Greta Pettini
Sanchini VirginiaSanchini Virginia
Sanchini Virginia
RPRuth Pat-Horenczyk
Ruth Pat-Horenczyk
BSBerta Sousa
Berta Sousa
MMMarianna Masiero
Marianna Masiero
KMKetti Mazzocco
Ketti Mazzocco
Background: Despite the continued progress of medicine, dealing with breast cancer is becoming a major socioeconomic challenge, particularly due to its increasing incidence. The ability to better manage and adapt to the entire care process depends not only on the type of cancer but also on the patient’s sociodemographic and psychological characteristics as well as on the social environment in which a person lives and interacts. Therefore, it is important to understand which factors may contribute to successful adaptation to breast cancer. To our knowledge, no studies have been performed on the combination effect of multiple psychological, biological, and functional variables in predicting the patient’s ability to bounce back from a stressful life event, such as a breast cancer diagnosis. Here we describe the study protocol of a multicenter clinical study entitled “Predicting Effective Adaptation to Breast Cancer to Help Women to BOUNCE Back” or, in short, BOUNCE. Objective: The aim of the study is to build a quantitative mathematical model of factors associated with the capacity for optimal adjustment to cancer and to study resilience through the cancer continuum in a population of patients with breast cancer. Methods: A total of 660 women with breast cancer will be recruited from five European cancer centers in Italy, Finland, Israel, and Portugal. Biomedical and psychosocial variables will be collected using the Noona Healthcare platform. Psychosocial, sociodemographic, lifestyle, and clinical variables will be measured every 3 months, starting from presurgery assessment (ie, baseline) to 18 months after surgery. Temporal data mining, time-series prediction, sequence classification methods, clustering time-series data, and temporal association rules will be used to develop the predictive model. Results: The recruitment process stared in January 2019 and ended in November 2021. Preliminary results have been published in a scientific journal and are available for consultation on the BOUNCE project website. Data analysis and dissemination of the study results will be performed in 2022. Conclusions: This study will develop a predictive model that is able to describe individual resilience and identify different resilience trajectories along the care process. The results will allow the implementation of tailored interventions according to patients’ needs, supported by eHealth technologies. Trial Registration: ClinicalTrials.gov NCT05095675; https://clinicaltrials.gov/ct2/show/NCT05095675 International Registered Report Identifier (IRRID): DERR1-10.2196/34564

1 January 2015 in Procedia Engineering
Verified
Journal Article
Open access
IHIra ira Haavisto
Ira ira Haavisto
GKGyöngyi Kovács
Gyöngyi Kovács
Procurement for humanitarian supply chains is often done by agencies that underlie public procurement regulations. These regulations tend to focus on transparency and openness, in other words, tender processes, price and quality. In other words, public procurement can be seen as hindering innovation through its rigidity. At the same time, humanitarian organizations face highly turbulent environments, sudden demand, and disaster- and context-specific requirements on items and technologies. Innovation in humanitarian supply chains needs to be swift but also robust, fitting an environment with disruptions in critical infrastructures such as energy and transportation. In spite of context-specific requirements, innovation does not stand alone but impacts on the supply chain through its requirements on suppliers, use in other echelons, and even, use across various sectors. Innovation thus cascades both upstream the supply chain and across sectors. Such cascades need to be identified, managed, or if detrimental, mitigated in the humanitarian supply chain. This paper therefore develops a framework for cascading innovation in humanitarian supply chains

12 April 2022 in Acta Oncologica
Verified
Journal Article
Closed access
RLRiikka-Leena Leskelä
Riikka-Leena Leskelä
EPEmmi Peltonen
Emmi Peltonen
IHIra ira Haavisto
Ira ira Haavisto
FHFredrik Herse
Fredrik Herse
SKSonja Korhonen
Sonja Korhonen
JKJussi Koivunen
Jussi Koivunen
Non-small cell lung cancer (NSCLC) is a leading cause of cancer mortality in the Western world. However, emerging treatment options and more patients directed to active treatments might improve the...


3 July 2026 in Journal of Medical Internet Research
Verified
Journal Article
Open access
CDCarina Dantas
Carina Dantas
MCMiriam Cabrita
Miriam Cabrita
MBMaciej Bobowicz
Maciej Bobowicz
HAHarm op den Akker
Harm op den Akker
XRXavier Rafael-Palou
Xavier Rafael-Palou
Elisio CostaElisio Costa
Elisio Costa
Background: The successful design and implementation of artificial intelligence (AI)–driven solutions in health care requires early and continuous multidisciplinary and multiprofessional collaboration. However, diverse disciplinary educational backgrounds, varying languages, and cultural or geographic differences can lead to misunderstandings. To bridge this gap, a structured approach to AI requirements specification can facilitate a shared terminology and a deep mutual understanding among stakeholders, serving both as a guide for technological development and as a means of defining clear pathways for clinical implementation. While technical requirements are well-established in traditional technology development domains, this structured approach remains relatively underused within clinical and social science contexts. Consequently, valuable insights derived from participatory and stakeholder-driven approaches are often overlooked, limiting the relevance and trustworthiness of AI systems in health care settings. Objective: This study presents a methodology for requirements gathering, specification, mapping, and verification, specifically engineered for the complex, multistakeholder environment of clinically applied AI. The methodology was implemented within the specific case of an international multidisciplinary project evaluating an AI-based prediction tool for neoadjuvant chemotherapy treatment response for breast cancer and forming a part of the developed AI validation framework. Methods: The process for AI requirements gathering, specification, and monitoring included 3 iterative rounds of discussion, engaging nearly 150 social, clinical, technical, ethical, and regulatory experts and patients across Europe, South America, North Africa, and Eurasia. It combines established requirements engineering methods (including the MoSCoW [Must have, Should have, Could have, Will not have] framework) with social innovation techniques to ensure inclusivity and contextual relevance. Results: A key finding is the successful development of a structured framework integrating participatory social innovation with formal requirements engineering in an international AI health care setting, through a traceable multisource workflow including clinical, ethical, and regulatory aspects. It is supplemented with an extensive list of 184 actionable consensus-based requirements, categorized by stakeholder group, providing valuable insights for AI researchers in the oncology field with the potential to be transferable to other digital health domains. The requirements align with the fairness, universality, traceability, usability, robustness, and explainability in the AI (FUTURE-AI) framework, ensuring the tool is trustworthy and comprehensive from a multistakeholder perspective, and ensuring comprehensive consideration of all elements of FUTURE-AI. Conclusions: The proposed methodology represents a significant advancement for requirements engineering in digital health by extending traditional technical processes to systematically incorporate nontechnical requirements from diverse global stakeholders. This unified approach is essential for ensuring AI solutions are not only technically robust but also clinically relevant, legally compliant, and socially acceptable.

29 January 2026 in Cancers
Verified
Journal Article
Open access
PDF file
THTuukka Hakkarainen
Tuukka Hakkarainen
IHIra ira Haavisto
Ira ira Haavisto
MNMikko Nuutinen
Mikko Nuutinen
YHYrjänä Hynninen
Yrjänä Hynninen
PPPaula Poikonen-Saksela
Paula Poikonen-Saksela
RLRiikka-Leena Leskelä
Riikka-Leena Leskelä
Introduction: Women with breast cancer experience psychological distress, and resilience-strengthening psychosocial support may improve their quality of life (QoL). Identifying those at risk of low QoL is challenging. This study evaluated the cost-effectiveness of a machine learning-based QoL predictor to support clinical decision-making regarding psychosocial support (sample size: 660). Methods: A decision tree cost–utility model was developed to compare four decision-making strategies in offering psychosocial support: the clinician alone, the QoL predictor alone, the clinician supported by the predictor, and no prediction with no psychosocial support. QoL after one year was used as a proxy for resilience. Costs, health outcomes, and net monetary benefits (NMBs) were estimated using a one-year time horizon. Incremental cost-effectiveness ratios (ICERs) were calculated and dominance assessed. A societal scenario analysis incorporated productivity losses. A probabilistic sensitivity analysis generated cost-effectiveness acceptability curves. Results: Clinicians supported by the QoL predictor produced the highest NMB (EUR 16,349) and the greatest quality-adjusted life year (QALY) gain (0.759), with an ICER of EUR 22,892 compared with the next least costly strategy. Clinician-only prediction and predictor-only approaches were dominated or extendedly dominated. Under the societal perspective, all strategies produced negative NMB values due to productivity losses, but the overall ranking remained unchanged. The probabilistic sensitivity analysis showed that the combined clinician and predictor strategy had a 69% probability of being cost-effective at a willingness to pay threshold of EUR 30,000. Conclusions: Combining clinician judgement with the machine learning-based QoL predictor improved the targeting of psychosocial support and was the most cost-effective strategy. Further prospective and comparative studies are needed to confirm its long-term effectiveness and cost-effectiveness in clinical practice.